Back to Newsroom

Sigilon Therapeutics Appoints David E. Moller, M.D., as Chief Scientific Officer

CAMBRIDGE, Mass., Jan. 4, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged Living Therapeutics, today announced the appointment of David E. Moller, M.D., to the position of Chief Scientific Officer. Dr. Moller brings a long history of experience in drug discovery and development to the company, including a focus on development of therapeutics for metabolic disorders and in the identification and evaluation of emerging technologies.